http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2254126-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 |
| filingDate | 2003-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35ac500e20be6a11ef4070e283d69f64 |
| publicationDate | 2005-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2254126-C2 |
| titleOfInvention | Method for combined therapy of strongylatosis in animals |
| abstract | FIELD: veterinary science. n SUBSTANCE: one should apply combined introduction of T-activin at the dosage of 5 mcg/kg once daily along with a single introduction of phenbendasol at the dosage of 5 mg/kg. Moreover, T-activin should be introduced for 3 d, and phenbendasol should be introduced simultaneously with the last injection of T-activin. Conditions for injecting immunomodulating agent and certain sequence of its injection along with antihelminthic preparation provide increased resistance to repeated infectioning in animals. n EFFECT: higher efficiency of combined therapy. n 2 ex, 2 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2514109-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2452489-C1 |
| priorityDate | 2003-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.